Aulos Bioscience

Aulos Bioscience is a private, pre-revenue biotech leveraging an artificial intelligence-driven antibody discovery platform from its partner Biolojic Design to create novel IL-2 therapeutics. The company's lead asset, imneskibart, is in Phase 2 development for solid tumors, with initial data showing clinical activity in melanoma and non-small cell lung cancer. Aulos aims to overcome the historical limitations of IL-2 by precisely directing its immune-activating power, positioning itself in the competitive but high-potential cytokine therapeutics space for oncology.

AI and machine learning platform (via partnership with Biolojic Design) for the rational design of epitope-specific human monoclonal antibodies. Used to design antibodies that bind specific functional sites on targets like IL-2.

The IL-2 therapeutic space is highly competitive, with numerous companies developing engineered IL-2 variants (e.g., 'not-α' IL-2 molecules), IL-2 fusion proteins, and other CD25-targeting approaches. Aulos competes with larger biopharma and biotech firms, and must demonstrate superior safety and efficacy to capture market share.